Consultation on NHS funding for Alzheimer’s treatments
Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab. Click here to read more.
Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab. Click here to read more.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
Create a network to share documents, knowledge and best practice with your colleagues. Set up a network to keep in touch with other people in your organisation or with shared interest groups across organisational boundaries.
Networks can be open to all or available only to a closed group defined by the administrator.
Join or create a network here.